Nonmuscle invasive bladder cancer - Pipeline Insight, 2021
This report can be delivered to the clients within 72 hours
DelveInsight’s, “Nonmuscle invasive bladder cancer - Pipeline Insight, 2021,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Nonmuscle invasive bladder cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Nonmuscle invasive bladder cancer: Overview
Non-muscle invasive bladder cancer (NMIBC) is cancer found in the tissue that lines the inner surface of the bladder. NMIBC accounts for 75% of all newly diagnosed cases of urothelial carcinoma of the bladder. Some of the common symptoms are hematuria (blood in the urine), frequent and urgent urination, pain in lower abdomen, and back pain. The diagnosis of bladder cancer is confirmed by direct visualization of the tumor and other mucosal abnormalities with endoscopic excision using cystoscopy and TURBT. The main treatments for when the cancer cells are found only in the bladder's inner lining (non-muscle-invasive bladder cancer) are surgery, immunotherapy and intravesical chemotherapy. Surgery, on its own or combined with other treatments, is used in most cases. Superficial, non-muscle invasive bladder cancers (NMIBCs) are managed with cystoscopic transurethral resection of all visible lesions followed by intravesical chemotherapy and/or immunotherapy.
'Nonmuscle invasive bladder cancer - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Nonmuscle invasive bladder cancer pipeline landscape is provided which includes the disease overview and Nonmuscle invasive bladder cancer treatment guidelines. The assessment part of the report embraces, in depth Nonmuscle invasive bladder cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Nonmuscle invasive bladder cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Nonmuscle invasive bladder cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Nonmuscle invasive bladder cancer Emerging Drugs
Further product details are provided in the report……..
Nonmuscle invasive bladder cancer: Therapeutic Assessment
This segment of the report provides insights about the different Nonmuscle invasive bladder cancer drugs segregated based on following parameters that define the scope of the report, such as:
Nonmuscle invasive bladder cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Nonmuscle invasive bladder cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nonmuscle invasive bladder cancer drugs.
Nonmuscle invasive bladder cancer Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Nonmuscle invasive bladder cancer - Pipeline Insight, 2021,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Nonmuscle invasive bladder cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Nonmuscle invasive bladder cancer: Overview
Non-muscle invasive bladder cancer (NMIBC) is cancer found in the tissue that lines the inner surface of the bladder. NMIBC accounts for 75% of all newly diagnosed cases of urothelial carcinoma of the bladder. Some of the common symptoms are hematuria (blood in the urine), frequent and urgent urination, pain in lower abdomen, and back pain. The diagnosis of bladder cancer is confirmed by direct visualization of the tumor and other mucosal abnormalities with endoscopic excision using cystoscopy and TURBT. The main treatments for when the cancer cells are found only in the bladder's inner lining (non-muscle-invasive bladder cancer) are surgery, immunotherapy and intravesical chemotherapy. Surgery, on its own or combined with other treatments, is used in most cases. Superficial, non-muscle invasive bladder cancers (NMIBCs) are managed with cystoscopic transurethral resection of all visible lesions followed by intravesical chemotherapy and/or immunotherapy.
'Nonmuscle invasive bladder cancer - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Nonmuscle invasive bladder cancer pipeline landscape is provided which includes the disease overview and Nonmuscle invasive bladder cancer treatment guidelines. The assessment part of the report embraces, in depth Nonmuscle invasive bladder cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Nonmuscle invasive bladder cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Nonmuscle invasive bladder cancer R&D. The therapies under development are focused on novel approaches to treat/improve Nonmuscle invasive bladder cancer.
This segment of the Nonmuscle invasive bladder cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Nonmuscle invasive bladder cancer Emerging Drugs
- UGN-102: UroGen Pharma
- Sasanlimab: Pfizer
Further product details are provided in the report……..
Nonmuscle invasive bladder cancer: Therapeutic Assessment
This segment of the report provides insights about the different Nonmuscle invasive bladder cancer drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Nonmuscle invasive bladder cancer
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Nonmuscle invasive bladder cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Nonmuscle invasive bladder cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nonmuscle invasive bladder cancer drugs.
Nonmuscle invasive bladder cancer Report Insights
- Nonmuscle invasive bladder cancer Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Nonmuscle invasive bladder cancer drugs?
- How many Nonmuscle invasive bladder cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Nonmuscle invasive bladder cancer?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Nonmuscle invasive bladder cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Nonmuscle invasive bladder cancer and their status?
- What are the key designations that have been granted to the emerging drugs?
- UroGen Pharma
- CG Oncolgy
- Sasanlimab
- Sesen Bio
- Theralase Technologies
- Asieris Pharmaceuticals
- Hamlet Pharma
- AstraZeneca
- Viralytics
- ImmunityBio
- Prokarium
- Vaxiion Therapeutics
- Janssen Pharmaceuticals
- Abraxis Bioscience
- LIPAC Oncology
- Rapamycin Holdings
- Incyte Corporation
- Taizhou Hanzhong biomedical
- UGN-102
- CG 0070
- Pfizer
- Vicineum
- TLD-1433
- APL-1202
- Alpha1H
- Durvalumab
- CVA 21
- Inbakicept
- Vesibax
- VAX-014
- Balversa
- ABI-009
- TSD-001
- eRapa
- Pemigatinib
- HX008
Introduction
Executive Summary
Nonmuscle invasive bladder cancer: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Nonmuscle invasive bladder cancer – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
UGN-102: UroGen Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
TLD 1433: Theralase Technologies
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
VAX-014: Vaxiion Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical/Discovery Stage Products
Comparative Analysis
Vesibax: Prokarium
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Nonmuscle invasive bladder cancer Key Companies
Nonmuscle invasive bladder cancer Key Products
Nonmuscle invasive bladder cancer- Unmet Needs
Nonmuscle invasive bladder cancer- Market Drivers and Barriers
Nonmuscle invasive bladder cancer- Future Perspectives and Conclusion
Nonmuscle invasive bladder cancer Analyst Views
Appendix
Executive Summary
Nonmuscle invasive bladder cancer: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Nonmuscle invasive bladder cancer – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
UGN-102: UroGen Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
TLD 1433: Theralase Technologies
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
VAX-014: Vaxiion Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical/Discovery Stage Products
Comparative Analysis
Vesibax: Prokarium
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Nonmuscle invasive bladder cancer Key Companies
Nonmuscle invasive bladder cancer Key Products
Nonmuscle invasive bladder cancer- Unmet Needs
Nonmuscle invasive bladder cancer- Market Drivers and Barriers
Nonmuscle invasive bladder cancer- Future Perspectives and Conclusion
Nonmuscle invasive bladder cancer Analyst Views
Appendix
LIST OF TABLES
Table 1 Total Products for Nonmuscle invasive bladder cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Nonmuscle invasive bladder cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Nonmuscle invasive bladder cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Nonmuscle invasive bladder cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
